| PubMed |
Abstract |
RScore(About this table) |
| 9359432 |
Mast AE, Higuchi DA, Huang ZF, Warshawsky I, Schwartz AL, Broze GJ Jr: Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J. 1997 Oct 15;327 ( Pt 2):577-83.
In addition, when the sulphation of glycosaminoglycans (GAGs) is prevented by growing the HepG2 cells in the presence of 30 mM sodium chlorate, TFPI binding is unaffected, whereas the binding of bovine lipoprotein lipase, a protein known to associate with cell-surface GAGs, falls to 50% of control levels. |
37(0,1,1,7) |
Details |
| 9409283 |
Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F: Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2964-74.
|
9(0,0,0,9) |
Details |
| 8948051 |
Iversen N, Sandset PM, Abildgaard U, Torjesen PA: Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thromb Res. 1996 Nov 15;84(4):267-78.
Treatment of the cells with heparinase III, with chondroitinase ABC lyase, or with sodium chlorate (to prevent sulfation) did not influence the binding of TFPI. |
4(0,0,0,4) |
Details |